Intellectual Disability
|
0.200 |
Biomarker
|
group |
BEFREE |
Xq27.1 duplication encompassing SOX3 has been implicated in the aetiology of X-linked hypopituitarism associated with intellectual disability and neural tube defects.
|
31678974 |
2019 |
Hypopituitarism
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xq27.1 Duplication Encompassing SOX3: Variable Phenotype and Smallest Duplication Associated with Hypopituitarism to Date - A Large Case Series of Unrelated Patients and a Literature Review.
|
31678974 |
2019 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We have identified several differentially expressed genes, including MET, KDR, and SOX3, which are associated with tumor invasiveness, malignancy, and unfavorable prognosis in glioblastoma patients.
|
29939324 |
2019 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Flow redistribution in liver segments by coil-embolization of variant HAs is a feasible technique that does not seem to compromise tumor response in patients undergoing M-PHP.
|
31650973 |
2019 |
Neural Tube Defects
|
0.030 |
Biomarker
|
group |
BEFREE |
Our data demonstrate that SOX3 duplication is a genomic imbalance involved in the pathogenesis of NTDs.
|
31299102 |
2019 |
Neural Tube Defects
|
0.030 |
Biomarker
|
group |
BEFREE |
Xq27.1 duplication encompassing SOX3 has been implicated in the aetiology of X-linked hypopituitarism associated with intellectual disability and neural tube defects.
|
31678974 |
2019 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
SOX3 plays a role in both normal neural development and carcinogenesis.
|
30209685 |
2019 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MTT, immunocytochemistry and Transwell assays were used to evaluate the effects of exogenous SOX3 overexpression on the viability, proliferation, migration and invasion of glioblastoma cells, respectively.
|
30209685 |
2019 |
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggested that miR-483 could suppress BC cell proliferation and promote BC cell apoptosis via targeting SOX3, which might be a potential therapeutic target in BC.
|
30915751 |
2019 |
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the aim of this work was to elucidate the role of SOX3 in glioblastoma.
|
30209685 |
2019 |
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have identified several differentially expressed genes, including MET, KDR, and SOX3, which are associated with tumor invasiveness, malignancy, and unfavorable prognosis in glioblastoma patients.
|
29939324 |
2019 |
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have identified several differentially expressed genes, including MET, KDR, and SOX3, which are associated with tumor invasiveness, malignancy, and unfavorable prognosis in glioblastoma patients.
|
29939324 |
2019 |
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the aim of this work was to elucidate the role of SOX3 in glioblastoma.
|
30209685 |
2019 |
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the aim of this work was to elucidate the role of SOX3 in glioblastoma.
|
30209685 |
2019 |
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have identified several differentially expressed genes, including MET, KDR, and SOX3, which are associated with tumor invasiveness, malignancy, and unfavorable prognosis in glioblastoma patients.
|
29939324 |
2019 |
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggested that miR-483 could suppress BC cell proliferation and promote BC cell apoptosis via targeting SOX3, which might be a potential therapeutic target in BC.
|
30915751 |
2019 |
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the aim of this work was to elucidate the role of SOX3 in glioblastoma.
|
30209685 |
2019 |
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
We have identified several differentially expressed genes, including MET, KDR, and SOX3, which are associated with tumor invasiveness, malignancy, and unfavorable prognosis in glioblastoma patients.
|
29939324 |
2019 |
Meningomyelocele
|
0.010 |
Biomarker
|
disease |
BEFREE |
The detection of an SOX3 microduplication by chromosomal microarray analysis (CMA) in two female fetuses with MMC prompted us to analyze retrospectively by qPCR this gene in a cohort of 53 fetuses with MMC.
|
31299102 |
2019 |
Usher Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In a mouse model of Usher syndrome type 3A deafness (gene <i>CLRN1</i>), we use AAV9-PHP.B encoding <i>Clrn1</i> to partially rescue hearing.
|
30581889 |
2019 |
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
We retrospectively analyzed pretreatment angiograms in all 32 patients that underwent M-PHP between January 2014 and March 2017 for unresectable liver metastases from ocular melanoma.
|
31650973 |
2019 |
Malignant melanoma of eye
|
0.010 |
Biomarker
|
disease |
BEFREE |
We retrospectively analyzed pretreatment angiograms in all 32 patients that underwent M-PHP between January 2014 and March 2017 for unresectable liver metastases from ocular melanoma.
|
31650973 |
2019 |
Cancer of Head
|
0.010 |
Biomarker
|
disease |
BEFREE |
The differences between the PHP and pancreatic head plexus I should be understood, even though liver function is not obviously affected after PHP excision for pancreatic head cancer.
|
31573097 |
2019 |
Autism Spectrum Disorders
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using autism as a model sex-biased disorder, the SOX3/SRY set was enriched in autism gene databases (FDR ≤ 0.05), and there were more de novo variations from the male autism spectrum disorder (ASD) samples under the SRY peaks compared to the random peaks (p < 0.024).
|
30537354 |
2019 |
Neurodevelopmental Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Here, we hypothesized that genes distinctively targeted by only one or both homologous proteins highly conserved across therian mammals, SOX3 and SRY, could induce sexual adaptive changes that result in a differential risk for neurodevelopmental disorders.
|
30537354 |
2019 |